Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality.
Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality.